KEGG   NETWORK: N10004Help
Entry
N10004                      Network                                

Name
Second/third-generation tyrosine kinase inhibitor to ALK fusion
Definition
(Alectinib,Ceritinib,Brigatinib,Lorlatinib) -| EML4-ALK*
  Expanded
(D10450,D10551,D10866,D11012) -| 238v2
Class
nt06210 ERK signaling
nt06266 Non-small cell lung cancer
nt06214 PI3K signaling
nt06219 JAK-STAT signaling
Type
Drug target
Gene
238  ALK; ALK receptor tyrosine kinase
Variant
238v2  First generation TKI-resistant ALK1 mutation
Perturbant
D10450  Alectinib
D10551  Ceritinib
D10866  Brigatinib
D11012  Lorlatinib
Reference
  Authors
Wu J, Savooji J, Liu D
  Title
Second- and third-generation ALK inhibitors for non-small cell lung cancer.
  Journal
J Hematol Oncol 9:19 (2016)
DOI:10.1186/s13045-016-0251-8
Reference
  Authors
Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, Eichinger L, Moran L, Huang WS, Liu S, Zou D, Wang Y, Mohemmad Q, Jang HG, Ye E, Narasimhan N, Wang F, Miret J, Zhu X, Clackson T, Dalgarno D, Shakespeare WC, Rivera VM
  Title
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
  Journal
Clin Cancer Res 22:5527-5538 (2016)
DOI:10.1158/1078-0432.CCR-16-0569
LinkDB All DBs

DBGET integrated database retrieval system